A study of ASP2138 given by itself or given with other cancer treatments in adults with stomach cancer, gastroesophageal junction cancer, or pancreatic cancer

2023-504514-29-00 Protocol 2138-CL-0101 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 18 Jun 2024 · Status Ongoing, recruiting · 3 EU/EEA countries · 18 sites · Protocol 2138-CL-0101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 378
Countries 3
Sites 18

Gastroesophageal Junction (GEJ) Adenocarcinoma

Key facts

Sponsor
Astellas Pharma Global Development Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
18 Jun 2024 → ongoing
Decision date (initial)
2024-01-30
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-504514-29-00
ClinicalTrials.gov
NCT05365581

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Gastroesophageal Junction (GEJ) Adenocarcinoma

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Astellas Pharma Global Development Inc.

Sponsor organisation
Astellas Pharma Global Development Inc.
Address
1 Astellas Way
City
Northbrook
Postcode
60062-6111
Country
United States

Scientific contact point

Organisation
Astellas Pharma Global Development Inc.
Contact name
Head of Clinical Trial Unit Regulatory Affairs

Public contact point

Organisation
Astellas Pharma Global Development Inc.
Contact name
Head of Clinical Trial Unit Regulatory Affairs

Locations

3 EU/EEA countries · 18 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 43 6
Italy Ongoing, recruiting 31 5
Spain Ongoing, recruiting 26 7
Rest of world
United States, Korea, Republic of, China, Japan
278

Investigational sites

France

6 sites · Ongoing, recruiting
Institut Paoli-Calmettes
Medical Oncology, 232 Boulevard De Sainte Marguerite, Bp 156, Marseille
Institut De Cancerologie De L Ouest
Medical Oncology, Bd Du Professeur Jacques Monod, 44800, St Herblain
Centre Hospitalier Universitaire De Poitiers
Gastro-Enterology and Medical Oncology, 2 Rue De La Miletrie, 86000, Poitiers
Institut Universitaire Du Cancer Toulouse-Oncopole
Clinical Research Unit, 1 Avenue Irene Joliot Curie, 31100, Toulouse
Institut Gustave Roussy
Medical Oncology/Phase 1 Depertment, 114 Rue Edouard Vaillant, 94800, Villejuif
Centre Leon Berard
Medical Oncology, 28 Rue Laennec, 69008, Lyon

Italy

5 sites · Ongoing, recruiting
Centro Ricerche Cliniche Di Verona S.r.l.
UOC Oncologia, Piazzale Ludovico Antonio Scuro 10, 37134, Verona
European Institute Of Oncology S.r.l.
Division of Early Drug Development, Via Giuseppe Ripamonti 435, 20141, Milan
Istituto Oncologico Veneto
UOC Oncology 1, Via Gattamelata 64, 35128, Padova
ASST Grande Ospedale Metropolitano Niguarda
Department of Oncology and Hematology-Oncology, Piazza Dell'ospedale Maggiore 3, 20162, Milan
Humanitas Research Hospital
Department of Oncology and Hematology-Oncology, Via Alessandro Manzoni 56, 20089, Rozzano

Spain

7 sites · Ongoing, recruiting
Hospital Universitari Vall D Hebron
Medical Oncology service, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Hm Nou Delfos
Medical Oncology service, Avinguda De Vallcarca 151, 08023, Barcelona
Hospital General Universitario De Elche
Medical Oncology service, Edificio 2, Camino De La Almazara 11, Elche
Hospital Universitario Miguel Servet
Medical Oncology service, Paseo De Isabel La Catolica 1-3, 50009, Zaragoza
University Clinical Hospital Virgen De La Arrixaca
Medical Oncology service, Carretera Madrid-Cartagena S/N, El Palmar, Murcia
Institut Catala D'oncologia
Medical Oncology service, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
Hospital De La Santa Creu I Sant Pau
Medical Oncology service, Carrer De San Quinti 89, 08041, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2024-06-18 2024-06-18
Italy 2024-08-01 2024-08-01
Spain 2025-06-18 2025-06-18

Application history

9 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-08-07 Italy Acceptable with conditions
2024-01-24
2024-01-25
2 SUBSTANTIAL MODIFICATION SM-3 2024-02-20 Italy Acceptable
2024-04-11
2024-04-29
3 SUBSTANTIAL MODIFICATION SM-4 2024-08-21 Italy Acceptable
2024-11-11
2024-11-12
4 SUBSTANTIAL MODIFICATION SM-5 2024-12-17 Italy Acceptable 2025-02-17
5 SUBSTANTIAL MODIFICATION SM-6 2024-12-20 Acceptable 2025-03-12
6 SUBSEQUENT ADDITION OF MSC APP-6 2025-01-04 2025-03-31
7 SUBSTANTIAL MODIFICATION SM-7 2025-04-16 Italy Acceptable
2025-06-16
2025-06-17
8 SUBSTANTIAL MODIFICATION SM-8 2025-11-04 Italy Acceptable
2026-01-15
2026-01-20
9 NON SUBSTANTIAL MODIFICATION NSM-2 2026-02-10 Italy Acceptable
2026-01-15
2026-02-10